Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-19-024628
Filing Date
2019-11-25
Accepted
2019-11-25 17:20:27
Documents
9
Period of Report
2019-12-18
Effectiveness Date
2019-11-25

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT def14a1119_actiniumpharma.htm DEF 14A 756913
2 GRAPHIC image001.jpg GRAPHIC 249494
3 GRAPHIC image002.jpg GRAPHIC 412972
4 GRAPHIC img_001.jpg GRAPHIC 15135
5 GRAPHIC img_002.jpg GRAPHIC 89610
6 GRAPHIC img_003.jpg GRAPHIC 36467
7 GRAPHIC img_004.jpg GRAPHIC 43834
8 GRAPHIC img_005.jpg GRAPHIC 5197
9 GRAPHIC img_006.jpg GRAPHIC 1085
  Complete submission text file 0001213900-19-024628.txt   1934953
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 191247049
SIC: 2834 Pharmaceutical Preparations